Weight management is an important component of care for people living with obesity. The SURMOUNT-1 trial evaluated the efficacy and safety of tirzepatide in adults living with obesity or overweight with at least one obesity-related complication, excluding type 2 diabetes.¹ At 72 weeks, participants receiving tirzepatide experienced significant weight reductions, with a mean reduction of 22.5% with the 15-mg dose (efficacy estimand) .¹ In addition, 62.9% of participants receiving 15 mg achieved ≥20% weight reduction at 72 weeks, based on the efficacy estimand.¹ Weight reduction was also accompanied by improvements in body composition.

In a subgroup assessed by DEXA, total fat mass decreased by 33.9% from baseline at 72 weeks , with reductions in total body fat mass approximately 3 times greater than reductions in lean mass .¹,² The most common adverse events were gastrointestinal in…